ArticleInvestigative ophthalmology & visual science2026
Comparative Effects of Riboflavin-UVA and Rose Bengal-Green Light Cross-Linking on Corneal Neovascularization.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to compare the effects of riboflavin-ultraviolet A (RF/UVA) cross-linking (CXL) and rose bengal-green light (RB/green light) CXL on corneal neovascularization (CNV) in rat eyes. Methods: Forty Wistar albino rats underwent CNV induction by corneal suture placement and were randomized into four groups: control, RF/UVA CXL, RB/green light CXL, and green light alone. Treatments were administered on day 3. Anterior segment (AS) photographs and AS-optical coherence tomography (AS-OCT) images were obtained on days 0, 3, 7, and 14, with days 7 and 14 defined as endpoints. Right corneas were analyzed using immunohistochemistry (IHC) for vascular endothelial growth factor (VEGF), lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and CD68, along with hematoxylin & eosin (H&E) staining and TUNEL assay. Left corneas were evaluated with ELISA for VEGF and CD68 levels. Results: The least CNV area was observed in the RF/UVA group on days 7 and 14 (P = 0.002 and P < 0.001, respectively). The RB/green light CXL group also demonstrated CNV area than the green light alone group on day 7 (P < 0.001). ELISA revealed significantly lower VEGF levels in all treatment groups compared with controls on day 7, whereas this reduction persisted only in the RF/UVA CXL group on day 14 (P < 0.001 and P = 0.049, respectively). VEGF and LYVE-1 immunostaining were significantly lower in the RF/UVA CXL group compared with the green light group at both time points. CD68 staining was reduced in both CXL groups. TUNEL analysis showed the highest keratocyte apoptotic index in the RF/UVA CXL group, followed by the RB/green light CXL group (both P < 0.001). Conclusions: Both CXL modalities suppressed inflammation and were effective in reducing hemangiogenesis, and lymphangiogenesis; however, the RF/UVA CXL group demonstrated superior overall efficacy than the RB/green light CXL group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.